Allovir Inc
Change company Symbol lookup
Select an option...
ALVR Allovir Inc
ALIZY Allianz SE
TEO Telecom Argentina SA
BAC Bank of America Corp
TNP Tsakos Energy Navigation Ltd
BFS Saul Centers Inc
ALNY Alnylam Pharmaceuticals Inc
VCNX Vaccinex Inc
XOM Exxon Mobil Corp
ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund
Go

Health Care : Biotechnology | Small Cap Value
Company profile

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

Closing Price
$6.50
Day's Change
-0.15 (-2.26%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.70
Day's Low
6.22
Volume
(Light)
Volume:
151,214

10-day average volume:
222,367
151,214

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.